Michael I. Halstead J.D.
Net Worth

Last updated:

What is Michael I. Halstead J.D. net worth?

The estimated net worth of Mr. Michael I. Halstead J.D. is at least $38,249,335 as of 13 Nov 2024. He owns shares worth $704,581 as insider, has earned $28,195,524 from insider trading and has received compensation worth at least $9,349,230 in Intra-Cellular Therapies, Inc..

What is the salary of Michael I. Halstead J.D.?

Mr. Michael I. Halstead J.D. salary is $849,930 per year as Executive Vice President, Gen. Counsel & Sec. in Intra-Cellular Therapies, Inc..

How old is Michael I. Halstead J.D.?

Mr. Michael I. Halstead J.D. is 52 years old, born in 1973.

What stocks does Michael I. Halstead J.D. currently own?

As insider, Mr. Michael I. Halstead J.D. owns shares in one company:

Company Title Shares Price per share Total value
Intra-Cellular Therapies, Inc. (ITCI) Executive Vice President, Gen. Counsel & Sec. 5,343 $131.87 $704,581

What does Intra-Cellular Therapies, Inc. do?

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI logo
ITCI
Intra-Cellular Therapies, Inc.
$131.87

Michael I. Halstead J.D. insider trading

Intra-Cellular Therapies, Inc.

Mr. Michael I. Halstead J.D. has made 60 insider trades between 2014-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 104,775 units of ITCI stock on 21 Dec 2021. As of 13 Nov 2024 he still owns at least 5,343 units of ITCI stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 18,714 $36.89 $690,359
Sale
Common Stock 5,343 $88.92 $475,100
Option
Stock Option (right to buy) 18,714 $36.89 $690,359
Sale
Common Stock 13,371 $88.17 $1,178,921
Sale
Common Stock 6,116 $89.63 $548,177
Sale
Common Stock 15,105 $88.72 $1,340,116
Option
Stock Option (right to buy) 22,869 $23.94 $547,484
Sale
Common Stock 1,648 $90.89 $149,787
Option
Common Stock 22,869 $23.94 $547,484
Sale
Common Stock 6,107 $65.82 $401,963
Sale
Common Stock 1,238 $66.7 $82,575
Option
Common Stock 7,345 N/A N/A
Option
Restricted Stock Units 7,345 N/A N/A
Sale
Common Stock 220 $66.81 $14,698
Sale
Common Stock 12,912 $66.14 $854,000
Option
Restricted Stock Units 13,132 N/A N/A
Option
Common Stock 13,132 N/A N/A
Sale
Common Stock 300 $68.54 $20,562
Sale
Common Stock 7,215 $69.54 $501,731
Sale
Common Stock 392 $70.13 $27,491
Option
Restricted Stock Units 7,907 N/A N/A
Option
Common Stock 7,907 N/A N/A
Sale
Common Stock 714 $67.17 $47,959
Sale
Common Stock 11,146 $66.37 $739,760
Option
Common Stock 46,115 $12.73 $587,044
Sale
Common Stock 30,360 $67.1 $2,037,156
Sale
Common Stock 18,154 $66.31 $1,203,792
Option
Stock Option (right to buy) 46,115 $12.73 $587,044
Sale
Common Stock 1,486 $67.8 $100,751
Option
Common Stock 3,885 $23.94 $93,007
Option
Stock Option (right to buy) 3,885 $23.94 $93,007
Sale
Common Stock 476 $44.15 $21,015
Sale
Common Stock 6,868 $44.99 $308,991
Option
Common Stock 7,344 N/A N/A
Sale
Common Stock 14,208 $43.2 $613,786
Option
Restricted Stock Units 7,344 N/A N/A
Sale
Common Stock 2,500 $42.52 $106,300
Sale
Common Stock 7,906 $47.03 $371,819
Option
Restricted Stock Units 7,906 N/A N/A
Option
Common Stock 7,906 N/A N/A
Sale
Common Stock 1,100 $48.68 $53,548
Sale
Common Stock 643 $47.23 $30,369
Sale
Common Stock 9,296 $46.56 $432,822
Sale
Common Stock 100 $49.6 $4,960
Option
Restricted Stock Units 11,139 N/A N/A
Option
Common Stock 11,139 N/A N/A
Sale
Common Stock 27,204 $53.94 $1,467,384
Option
Common Stock 50,000 $15.47 $773,500
Sale
Common Stock 22,796 $53.48 $1,219,130
Option
Stock Option (right to buy) 50,000 $15.47 $773,500
Sale
Common Stock 3,718 $52.38 $194,749
Sale
Common Stock 4,188 $51.62 $216,185
Option
Restricted Stock Units 7,906 N/A N/A
Option
Common Stock 7,906 N/A N/A
Sale
Common Stock 6,589 $55.69 $366,941
Option
Restricted Stock Units 11,139 N/A N/A
Sale
Common Stock 4,550 $54.98 $250,159
Option
Common Stock 11,139 N/A N/A
Sale
Common Stock 12,755 $40.81 $520,532
Option
Restricted Stock Units 19,639 N/A N/A
Sale
Common Stock 4,380 $40.12 $175,726
Sale
Common Stock 2,504 $41.74 $104,517
Option
Common Stock 19,639 N/A N/A
Sale
Common Stock 22,620 $48.62 $1,099,784
Option
Stock Option (right to buy) 63,717 $15.73 $1,002,268
Option
Common Stock 63,717 $15.73 $1,002,268
Sale
Common Stock 4,344 $44.87 $194,915
Option
Common Stock 25,000 $13.86 $346,500
Sale
Common Stock 104,775 $47.84 $5,012,436
Sale
Common Stock 8,690 $45.74 $397,481
Option
Common Stock 88,146 $17.57 $1,548,725
Sale
Common Stock 36,434 $46.87 $1,707,662
Sale
Common Stock 11,139 N/A N/A
Sale
Common Stock 11,139 N/A N/A
Option
Restricted Stock Units 11,139 N/A N/A
Option
Common Stock 11,139 N/A N/A
Sale
Common Stock 19,638 N/A N/A
Sale
Common Stock 19,638 $31.86 $625,667
Option
Common Stock 19,638 N/A N/A
Option
Restricted Stock Units 19,638 N/A N/A
Sale
Common Stock 16,160 N/A N/A
Sale
Common Stock 16,160 $15.7 $253,631
Option
Common Stock 16,160 N/A N/A
Option
Restricted Stock Units 16,160 N/A N/A
Sale
Common Stock 79,425 $27.78 $2,206,029
Option
Common Stock 75,000 N/A N/A
Option
Stock Option (right to buy) 75,000 N/A N/A
Sale
Common Stock 79,425 N/A N/A
Sale
Common Stock 19,638 N/A N/A
Option
Common Stock 19,638 N/A N/A
Option
Restricted Stock Units 19,638 N/A N/A
Sale
Common Stock 21,458 N/A N/A
Option
Common Stock 21,458 N/A N/A
Option
Restricted Stock Units 21,458 N/A N/A
Option
Restricted Stock Units 21,458 N/A N/A
Option
Common Stock 21,458 N/A N/A
Sale
Common Stock 7,807 N/A N/A
Sale
Common Stock 7,807 $32.95 $257,225
Sale
Common Stock 7,807 $32.95 $257,225
Sale
Common Stock 3,108 N/A N/A
Sale
Common Stock 21,458 N/A N/A
Option
Restricted Stock Units 3,108 N/A N/A
Option
Common Stock 3,108 N/A N/A
Option
Common Stock 21,458 N/A N/A
Option
Restricted Stock Units 21,458 N/A N/A
Option
Common Stock 21,458 N/A N/A
Option
Restricted Stock Units 21,458 N/A N/A
Sale
Common Stock 7,807 N/A N/A
Sale
Common Stock 25,500 N/A N/A
Sale
Common Stock 1,560 N/A N/A
Option
Common Stock 3,108 N/A N/A
Sale
Common Stock 2,660 N/A N/A
Option
Restricted Stock Units 3,108 N/A N/A
Option
Common Stock 5,297 N/A N/A
Option
Restricted Stock Units 5,297 N/A N/A
Sale
Common Stock 1,601 N/A N/A
Option
Common Stock 3,107 N/A N/A
Option
Restricted Stock Units 3,107 N/A N/A
Purchase
Common Stock 13,000 N/A N/A
Purchase
Common Stock 7,000 N/A N/A

Intra-Cellular Therapies key executives

Intra-Cellular Therapies, Inc. executives and other stock owners filed with the SEC: